Antipsychotic Drugs Rapidly Induce Dopamine Neuron Depolarization Block in a Developmental Rat Model of Schizophrenia
Valenti et al.
J. Neurosci. 2011;31:12330-12338.
ABSTRACT
| FULL TEXT
Historical perspective on antipsychotic long-acting injections
Johnson
Br. J. Psychiatry 2009;195:S7-S12.
ABSTRACT
| FULL TEXT
Cognitive-behavioural therapy for severe mental disorders: back to the future?
Scott
Br. J. Psychiatry 2008;192:401-403.
ABSTRACT
| FULL TEXT
How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Owens
Adv. Psychiatr. Treat. 2008;14:17-28.
ABSTRACT
| FULL TEXT
Management
Puri and Treasaden
Emergencies in Psychiatry 2008;1:med-9780198530800-div1-38-med-9780198530800-div1-38.
FULL TEXT
Sociodemographic, Functional and Clinical Correlates in Outpatients with Schizophrenia: Comparison with Affective Disorders
Wheeler
Aust N Z J Psychiatry 2007;41:809-818.
ABSTRACT
| FULL TEXT
New antipsychotic agents are much awaited.
Chakraborti
BMJ 2006;332:1511-1511.
FULL TEXT
Trends in Antipsychotic Prescribing in Schizophrenia in Auckland
Wheeler et al.
Australas Psychiatry 2006;14:169-174.
ABSTRACT
| FULL TEXT
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia
Ezewuzie and Taylor
J Psychopharmacol 2006;20:86-90.
ABSTRACT
Rational pharmacotherapy in early psychosis
REMINGTON
Br. J. Psychiatry 2005;187:s77-s84.
ABSTRACT
| FULL TEXT
Why aren't depot antipsychotics prescribed more often and what can be done about it?
Patel and David
Adv. Psychiatr. Treat. 2005;11:203-211.
ABSTRACT
| FULL TEXT
Construct Validity of the Animal Latent Inhibition Model of Selective Attention Deficits in Schizophrenia
Lubow
Schizophr Bull 2005;31:139-153.
ABSTRACT
| FULL TEXT
Use of Electronic Medical Record Data for Quality Improvement in Schizophrenia Treatment
Owen et al.
J Am Med Inform Assoc 2004;11:351-357.
ABSTRACT
| FULL TEXT
Long-Term K+ Channel-Mediated Dampening of Dopamine Neuron Excitability by the Antipsychotic Drug Haloperidol
Hahn et al.
J. Neurosci. 2003;23:10859-10866.
ABSTRACT
| FULL TEXT
Recent Developments in Pharmacotherapy for the Acutely Psychotic Patient
Daniel
J Am Psychiatr Nurses Assoc 2002;8:S40-S47.
A 23-Year-Old Man With Schizophrenia
Goff
JAMA 2002;287:3249-3257.
FULL TEXT
Interaction of Dopamine D1 and NMDA Receptors Mediates Acute Clozapine Potentiation of Glutamate EPSPs in Rat Prefrontal Cortex
Chen and Yang
J. Neurophysiol. 2002;87:2324-2336.
ABSTRACT
| FULL TEXT
A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia
Breier et al.
Arch Gen Psychiatry 2002;59:441-448.
ABSTRACT
| FULL TEXT
Determining the optimal dose of haloperidol in first-episode psychosis
Oosthuizen et al.
J Psychopharmacol 2001;15:251-255.
ABSTRACT
High dose neuroleptics -- who gives them and why?
Wilkie et al.
The Psychiatrist 2001;25:179-183.
ABSTRACT
| FULL TEXT
The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers
McCartan et al.
J Psychopharmacol 2001;15:96-104.
ABSTRACT
Low dose typical antipsychotics - a brief evaluation
Taylor
The Psychiatrist 2000;24:465-468.
FULL TEXT
The Current Status of Tardive Dyskinesia
Sachdev
Aust N Z J Psychiatry 2000;34:355-369.
ABSTRACT
| FULL TEXT
Induction of NF-kappa B Activity during Haloperidol-Induced Oxidative Toxicity in Clonal Hippocampal Cells: Suppression of NF-kappa B and Neuroprotection by Antioxidants
Post et al.
J. Neurosci. 1998;18:8236-8246.
ABSTRACT
| FULL TEXT
Review: chlorpromazine reduces relapse but increases adverse events in schizophrenia
Barnes
Evid. Based Ment. Health 1998;1:83-83.
FULL TEXT
Psychopharmacological Treatment of Schizophrenia: What Social Workers Need to Know
Bentley
Research on Social Work Practice 1998;8:384-405.
ABSTRACT
Medication Removal and Research in Psychotic Disorders
Baldessarini et al.
Arch Gen Psychiatry 1998;55:281-283.
FULL TEXT
Clozapine and Haloperidol Modulate N-Methyl-D-aspartate- and Non-N-Methyl-D-aspartate Receptor-Mediated Neurotransmission in Rat Prefrontal Cortical Neurons In Vitro
Arvanov et al.
J. Pharmacol. Exp. Ther. 1997;283:226-234.
ABSTRACT
| FULL TEXT
Clinical Risk Following Abrupt and Gradual Withdrawal of Maintenance Neuroleptic Treatment
Viguera et al.
Arch Gen Psychiatry 1997;54:49-55.
ABSTRACT
Drug Strategies and Treatment-Resistant Schizophrenia
Pantelis and Barnes
Aust N Z J Psychiatry 1996;30:20-37.
ABSTRACT
The drug treatment of patients with schizophrenia
DTB 1995;33:81-86.
ABSTRACT
| FULL TEXT
Plasma Haloperidol Levels and Clinical Effects in Schizophrenia and Schizoaffective Disorder
Volavka et al.
Arch Gen Psychiatry 1995;52:837-845.
ABSTRACT
Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients
Jeste et al.
Arch Gen Psychiatry 1995;52:756-765.
ABSTRACT
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini et al.
Arch Gen Psychiatry 1995;52:189-192.
ABSTRACT
The effects of remoxipride and chlorpromazine on eye movements and psychomotor performance in healthy volunteers
King et al.
J Psychopharmacol 1995;9:143-149.
ABSTRACT
Lower-Dose Therapy With Traditional Neuroleptics in Chronically Hospitalized Schizophrenic Patients
Smith
Arch Gen Psychiatry 1994;51:427-429.
ABSTRACT
Antipsychotic Drug Doses in a Schizophrenia Inpatient Unit
Galletly
Aust N Z J Psychiatry 1992;26:574-576.
ABSTRACT
Clinical and Biologic Response to Clozapine in Patients With Schizophrenia: Crossover Comparison With Fluphenazine
Pickar et al.
Arch Gen Psychiatry 1992;49:345-353.
ABSTRACT
Haloperidol Blood Levels and Clinical Effects
Volavka et al.
Arch Gen Psychiatry 1992;49:354-361.
ABSTRACT
Acute Extrapyramidal Syndromes in Neuroleptic-Treated Elders: A Pilot Study
Ganzini et al.
J Geriatr Psychiatry Neurol 1991;4:222-225.
ABSTRACT
Optimal Dose of Neuroleptic in Acute Schizophrenia: A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose
McEvoy et al.
Arch Gen Psychiatry 1991;48:739-745.
ABSTRACT
Dosage of Haloperidol for Schizophrenia
Rifkin et al.
Arch Gen Psychiatry 1991;48:166-170.
ABSTRACT
A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten et al.
Arch Gen Psychiatry 1990;47:754-758.
ABSTRACT
Fluphenazine Dose, Clinical Response, and Extrapyramidal Symptoms During Acute Treatment
Levinson et al.
Arch Gen Psychiatry 1990;47:761-768.
ABSTRACT
Risk Factors for Neuroleptic Malignant Syndrome: A Case-Control Study
Keck et al.
Arch Gen Psychiatry 1989;46:914-918.
ABSTRACT
Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer et al.
Arch Gen Psychiatry 1989;46:922-928.
ABSTRACT
The Use of Seclusion: A Comparison of Two Psychiatric Intensive Care Units
Hafner et al.
Aust N Z J Psychiatry 1989;23:235-239.
ABSTRACT
Psychiatry
Glass and Freedman
JAMA 1989;261:2883-2885.
ABSTRACT
Dopamine Receptor Occupancy and Plasma Haloperidol Levels
Wolkin et al.
Arch Gen Psychiatry 1989;46:482-483.
ABSTRACT
Atypical Neuroleptics, Dose-Response Relationships, and Treatment-Resistant Psychosis
Cohen et al.
Arch Gen Psychiatry 1989;46:381-383.
ABSTRACT
Who Should Receive Clozapine?
Marder and Van Putten
Arch Gen Psychiatry 1988;45:865-867.
ABSTRACT
